(0.33%) 5 116.76 points
(0.33%) 38 364 points
(0.38%) 15 988 points
(-0.95%) $83.05
(5.25%) $2.02
(0.33%) $2 354.90
(0.44%) $27.66
(4.12%) $960.10
(-0.27%) $0.932
(-0.46%) $10.97
(-0.59%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA)...
Stats | |
---|---|
本日の出来高 | 2 680.00 |
平均出来高 | 25 474.00 |
時価総額 | 69.25M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-1.000 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.34 |
ATR14 | $0.123 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Cataldi Fabio | Buy | 21 138 | Restricted Stock Unit |
2024-02-29 | Oakes Gregory | Buy | 54 454 | Restricted Stock Unit |
2023-05-30 | Batycky Alka | Buy | 3 600 | Stock Option (right to buy) |
2023-05-30 | Batycky Alka | Buy | 0 | |
2023-05-23 | Mayleben Timothy M | Buy | 18 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.60 |
Last 91 transactions |
Buy: 96 412 664 | Sell: 25 476 546 |
Landos Biopharma, Inc. 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Landos Biopharma, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2022 |
収益: | $0 |
総利益: | $-577 000 (0.00 %) |
EPS: | $-9.44 |
FY | 2021 |
収益: | $18.00M |
総利益: | $18.00M (100.00 %) |
EPS: | $-0.981 |
Financial Reports:
No articles found.
Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。